Abstract: A respiration promoting apparatus and a method for promoting respiration for coordinately stimulating two Phrenic nerves of a patient for activating a diaphragm of the patient comprising a first coil unit (91), a second coil unit (92) and a bracket structure (93). The first coil unit (91) has a first forward face (911) configured to be positioned at the patient to stimulate a first Phrenic nerve of the two Phrenic nerves (62) of the patient. The second coil unit (92) has a second forward face (921) configured to be positioned at the patient to stimulate a second Phrenic nerve. The bracket structure (93) is coupled to the first coil unit (91) and the second coil unit (92) and is adjustable such that positions and orientations of the first coil unit (91) and of the second coil unit (92) are adapted. The bracket structure (93) has a third forward face (918, 928, 932) configured to be positioned at the patient.

Abstract: A system performs static program analysis with artifact reuse. The system identifies artifacts associated with the software program being analyzed. The system processes the identified artifacts for performing static program analysis and transmits either the artifacts or identifiers for the artifacts to a second processing device for performing program analysis. The second processing device receives the artifacts and uses the received identifiers to retrieve the artifacts from a networked storage system. The second device also retrieves stored summaries of previous program analysis from the networked storage system. The program analysis uses the retrieved artifacts to generate work units for static program analysis. The analysis is performed only for those work units that are determined to remain unchanged from previous static program analysis cycles.

Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.

Abstract: The present disclosure is drawn to, among other things, a magnetoresistive device and a magnetoresistive memory comprising a plurality of such magnetoresistive devices. In some aspects, a magnetoresistive device may include a magnetically fixed region, a magnetically free region above or below the magnetically fixed region, and an intermediate region positioned between the magnetically fixed region and the magnetically free region, wherein the intermediate region includes a first dielectric material. The magnetoresistive device may also include encapsulation layers formed on opposing side walls of the magnetically free region, wherein the encapsulation layers include the first dielectric material.

Abstract: Magnetoresistive device architectures and methods for manufacturing are presented that facilitate integration of process steps associated with forming such devices into standard process flows used for surrounding logic/circuitry. In some embodiments, the magnetoresistive device structures are designed such that the devices are able to fit within the vertical dimensions of the integrated circuit associated with a single metal layer and a single layer of interlayer dielectric material. Integrating the processing for the magnetoresistive devices can include using the same standard interlayer dielectric material as used in the surrounding circuits on the integrated circuit as well as using standard vias to interconnect to at least one of the electrodes of the magnetoresistive devices.

Abstract: Compounds that inhibit PI3K?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3K?.

Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.

Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.

Abstract: Composite electrodes and their methods of manufacture are disclosed. In one embodiment, an electrode may include a first layer including first particles, a second layer including conductive nanowires, and a third layer comprising second particles. The second layer may be disposed between and in electrical contact with the first layer and the third layer. The composite electrode may be substantially transparent in some embodiments.

Abstract: A system (100) includes an echocardiogram measurement tool (150) that determines a subset (152) of measurements from a list of echocardiogram measurements according to a view of an ultrasound imaging sequence (110) and a mapping (154) between the view and the subset of measurements.

Abstract: A patient monitor (8) includes a display (10). Patient values (38) are obtained for one or more known variables of a risk prediction function (30). One or more unknown variables of the risk prediction function are determined, and at least one hyperplane (40) is defined as values assumable by the one or more unknown variables. Values of the risk prediction function are computed over the at least one hyperplane using the obtained patient values. A visualization template is selected from a database of visualization templates (50) using template selection indices including the risk prediction function and the one or more unknown variables. Using the visualization template, a visualization (52) of the computed values of the risk prediction function over the at least one hyperplane is displayed.

Abstract: Magnetoresistive device architectures and methods for manufacturing are presented that facilitate integration of process steps associated with forming such devices into standard process flows used for surrounding logic/circuitry. In some embodiments, the magnetoresistive device structures are designed such that the devices are able to fit within the vertical dimensions of the integrated circuit associated with a single metal layer and a single layer of interlayer dielectric material. Integrating the processing for the magnetoresistive devices can include using the same standard interlayer dielectric material as used in the surrounding circuits on the integrated circuit as well as using standard vias to interconnect to at least one of the electrodes of the magnetoresistive devices.

Abstract: A system (100) includes an echocardiogram measurement tool (150) that determines a subset (152) of measurements from a list of echocardiogram measurements according to a view of an ultrasound imaging sequence (110) and a mapping (154) between the view and the subset of measurements.

Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.

Abstract: In accordance with an embodiment, described herein is a system and method for orchestration of operations associated with a media content environment, including use of a prepare-proceed workflow process (workflow) that supports definition and use of different payment/billing systems or processes. A payment/billing server, for use with the media content environment dynamically generates workflows for use in processing payments associated with products. Upon receipt of a request to purchase a product, the payment/billing server generates a workflow to process a payment, including querying a product subsystem to determine pre-authorization steps required for purchase of the product and executing the pre-authorization steps; querying a transaction subsystem to determine a transaction information required for authorization; and querying a payment processor for authorization of the transaction.

Abstract: Magnetoresistive device architectures and methods for manufacturing are presented that facilitate integration of process steps associated with forming such devices into standard process flows used for surrounding logic/circuitry. In some embodiments, the magnetoresistive device structures are designed such that the devices are able to fit within the vertical dimensions of the integrated circuit associated with a single metal layer and a single layer of interlayer dielectric material. Integrating the processing for the magnetoresistive devices can include using the same standard interlayer dielectric material as used in the surrounding circuits on the integrated circuit as well as using standard vias to interconnect to at least one of the electrodes of the magnetoresistive devices.

Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.

Abstract: The present disclosure is drawn to, among other things, a magnetoresistive memory. The magnetoresistive memory comprises a plurality of magnetoresistive memory devices, wherein each magnetoresistive memory device includes a fixed magnetic region, a free magnetic region, and an intermediate region disposed in between the fixed and free magnetic regions. The magnetoresistive memory further comprises a first conductor extending adjacent each magnetoresistive memory device of the plurality of magnetoresistive devices, wherein the first conductor is in electrical contact with the free magnetic region of each magnetoresistive memory device.

Abstract: Disclosed is a rotary indexing table (10) having an output flange (12) which is suitable for receiving a workpiece, mounted on a housing (14) of said rotary indexing table (10) for rotation about an axis of rotation (A) and drivingly connected to at least one drive element (24) which engages a driving groove (22) in a cylindrical cam (20) which can be driven by a motor, the cylindrical cam (20) being disposed asymmetrically to the axis of rotation (A) of the output flange (12).